|
Name |
Ethyl heptadecanoate
|
Molecular Formula | C19H38O2 | |
IUPAC Name* |
ethyl heptadecanoate
|
|
SMILES |
CCCCCCCCCCCCCCCCC(=O)OCC
|
|
InChI |
InChI=1S/C19H38O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19(20)21-4-2/h3-18H2,1-2H3
|
|
InChIKey |
KNXMUFRWYNVISA-UHFFFAOYSA-N
|
|
Synonyms |
Ethyl heptadecanoate; 14010-23-2; ETHYL MARGARATE; Heptadecanoic acid, ethyl ester; Heptadecanoic Acid Ethyl Ester; Ethyl n-heptadecanoate; Margaric Acid Ethyl Ester; Ethylheptadecanoate; EINECS 237-822-6; MFCD00026658; SCHEMBL346642; n-Heptadecanoic acid ethyl ester; Ethyl heptadecanoate, AldrichCPR; DTXSID10161232; NSC137831; ZINC70454038; AKOS015839865; NSC 137831; NSC-137831; AS-60563; DB-042506; CS-0185611; FT-0636996; H0526; H11957; A807621; J-007354
|
|
CAS | 14010-23-2 | |
PubChem CID | 26397 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 298.5 | ALogp: | 8.4 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 17 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 21 | QED Weighted: | 0.244 |
Caco-2 Permeability: | -4.81 | MDCK Permeability: | 0.00001550 |
Pgp-inhibitor: | 0.009 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.883 |
30% Bioavailability (F30%): | 0.997 |
Blood-Brain-Barrier Penetration (BBB): | 0.108 | Plasma Protein Binding (PPB): | 97.44% |
Volume Distribution (VD): | 2.402 | Fu: | 1.46% |
CYP1A2-inhibitor: | 0.381 | CYP1A2-substrate: | 0.185 |
CYP2C19-inhibitor: | 0.441 | CYP2C19-substrate: | 0.062 |
CYP2C9-inhibitor: | 0.187 | CYP2C9-substrate: | 0.937 |
CYP2D6-inhibitor: | 0.216 | CYP2D6-substrate: | 0.039 |
CYP3A4-inhibitor: | 0.318 | CYP3A4-substrate: | 0.062 |
Clearance (CL): | 4.519 | Half-life (T1/2): | 0.197 |
hERG Blockers: | 0.269 | Human Hepatotoxicity (H-HT): | 0.011 |
Drug-inuced Liver Injury (DILI): | 0.249 | AMES Toxicity: | 0.005 |
Rat Oral Acute Toxicity: | 0.032 | Maximum Recommended Daily Dose: | 0.012 |
Skin Sensitization: | 0.958 | Carcinogencity: | 0.052 |
Eye Corrosion: | 0.964 | Eye Irritation: | 0.962 |
Respiratory Toxicity: | 0.9 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000258 | 0.952 | D07ILQ | 0.667 | ||||
ENC000419 | 0.950 | D00FGR | 0.552 | ||||
ENC000496 | 0.828 | D00AOJ | 0.549 | ||||
ENC000280 | 0.818 | D0Z5SM | 0.541 | ||||
ENC001218 | 0.800 | D0O1PH | 0.500 | ||||
ENC001234 | 0.791 | D05ATI | 0.466 | ||||
ENC000497 | 0.783 | D00MLW | 0.455 | ||||
ENC000271 | 0.781 | D00STJ | 0.403 | ||||
ENC000356 | 0.754 | D0G2KD | 0.402 | ||||
ENC000474 | 0.750 | D0T9TJ | 0.398 |